Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy
Objective To evaluate the functional benefits (best corrected visual acuity (BCVA), central subfield thickness, injection loads, central venous pressure (CVP)) of a laser-induced chorioretinal anastomosis (L-CRA) in patients with central retinal vein occlusion (CRVO) treated with ranibizumab compare...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-09-01
|
| Series: | BMJ Open Ophthalmology |
| Online Access: | https://bmjophth.bmj.com/content/6/1/e000728.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203278015463424 |
|---|---|
| author | David A Mackey Paul G Sanfilippo Fred K Chen Ian L McAllister Lynne A Smithies |
| author_facet | David A Mackey Paul G Sanfilippo Fred K Chen Ian L McAllister Lynne A Smithies |
| author_sort | David A Mackey |
| collection | DOAJ |
| description | Objective To evaluate the functional benefits (best corrected visual acuity (BCVA), central subfield thickness, injection loads, central venous pressure (CVP)) of a laser-induced chorioretinal anastomosis (L-CRA) in patients with central retinal vein occlusion (CRVO) treated with ranibizumab compared with ranibizumab monotherapy.Methods and Analysis This is a post-hoc analysis of the 2-year randomised ranibizumab plus L-CRA for CRVO trial. Twenty-four patients (82.5%) developed a functioning or successful L-CRA; outcome effects were monitored in the monthly as-needed ranibizumab phase from months 7 to 24 and compared with the ranibizumab monotherapy group (n=29).Results From months 7 to 24, the mean (95% CI) injection load for the functioning L-CRA group was 2.18 (1.57 to 2.78) compared with 7.07 (6.08 to 8.06) for the control group (p<0.0001). The mean BCVA was averaged across all timepoints between the control and functioning L-CRA groups (average difference=11.46 (3.16 to 19.75) letters, p=0.01). At 2 years, there was an 82.5% reduction in the odds of high CVP (greater or equal to central retinal artery diastolic pressure) for those with a successful L-CRA compared with controls (p<0.0001).Conclusion For patients with CRVO, adding L-CRA as a causal-based treatment to conventional therapy reduced CVP and injection loads and offered improved BCVA.Trial registration number ACTRN12612000004864. |
| format | Article |
| id | doaj-art-dd2c9bcca56f4e31af0c31fccc9e3a97 |
| institution | OA Journals |
| issn | 2397-3269 |
| language | English |
| publishDate | 2021-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Ophthalmology |
| spelling | doaj-art-dd2c9bcca56f4e31af0c31fccc9e3a972025-08-20T02:11:34ZengBMJ Publishing GroupBMJ Open Ophthalmology2397-32692021-09-016110.1136/bmjophth-2021-000728Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapyDavid A Mackey0Paul G Sanfilippo1Fred K Chen2Ian L McAllister3Lynne A Smithies4Centre for Ophthalmology and Visual Science, University of Western Australia, Lions Eye Institute, Perth, Western Australia, Australia1Department of Neurosciences, Central Clinical School, Monash University, Melbourne, VIC, AustraliaOphthalmology Department, Royal Perth Hospital, Perth, Western Australia, AustraliaUniversity of Western Australia, Lions Eye Institute, Nedlands, Western Australia, AustraliaLions Eye Institute (Centre for Ophthalmology and Visual Science), University of Western Australia, Perth, Western Australia, AustraliaObjective To evaluate the functional benefits (best corrected visual acuity (BCVA), central subfield thickness, injection loads, central venous pressure (CVP)) of a laser-induced chorioretinal anastomosis (L-CRA) in patients with central retinal vein occlusion (CRVO) treated with ranibizumab compared with ranibizumab monotherapy.Methods and Analysis This is a post-hoc analysis of the 2-year randomised ranibizumab plus L-CRA for CRVO trial. Twenty-four patients (82.5%) developed a functioning or successful L-CRA; outcome effects were monitored in the monthly as-needed ranibizumab phase from months 7 to 24 and compared with the ranibizumab monotherapy group (n=29).Results From months 7 to 24, the mean (95% CI) injection load for the functioning L-CRA group was 2.18 (1.57 to 2.78) compared with 7.07 (6.08 to 8.06) for the control group (p<0.0001). The mean BCVA was averaged across all timepoints between the control and functioning L-CRA groups (average difference=11.46 (3.16 to 19.75) letters, p=0.01). At 2 years, there was an 82.5% reduction in the odds of high CVP (greater or equal to central retinal artery diastolic pressure) for those with a successful L-CRA compared with controls (p<0.0001).Conclusion For patients with CRVO, adding L-CRA as a causal-based treatment to conventional therapy reduced CVP and injection loads and offered improved BCVA.Trial registration number ACTRN12612000004864.https://bmjophth.bmj.com/content/6/1/e000728.full |
| spellingShingle | David A Mackey Paul G Sanfilippo Fred K Chen Ian L McAllister Lynne A Smithies Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy BMJ Open Ophthalmology |
| title | Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy |
| title_full | Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy |
| title_fullStr | Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy |
| title_full_unstemmed | Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy |
| title_short | Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy |
| title_sort | functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy |
| url | https://bmjophth.bmj.com/content/6/1/e000728.full |
| work_keys_str_mv | AT davidamackey functionalbenefitsofachorioretinalanastomosisat2yearsineyeswithacentralretinalveinocclusiontreatedwithranibizumabcomparedwithranibizumabmonotherapy AT paulgsanfilippo functionalbenefitsofachorioretinalanastomosisat2yearsineyeswithacentralretinalveinocclusiontreatedwithranibizumabcomparedwithranibizumabmonotherapy AT fredkchen functionalbenefitsofachorioretinalanastomosisat2yearsineyeswithacentralretinalveinocclusiontreatedwithranibizumabcomparedwithranibizumabmonotherapy AT ianlmcallister functionalbenefitsofachorioretinalanastomosisat2yearsineyeswithacentralretinalveinocclusiontreatedwithranibizumabcomparedwithranibizumabmonotherapy AT lynneasmithies functionalbenefitsofachorioretinalanastomosisat2yearsineyeswithacentralretinalveinocclusiontreatedwithranibizumabcomparedwithranibizumabmonotherapy |